A Phase 1 Study of A Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 In Patients With Recurrent Metastatic, Castration-Resistant Prostate Cancer (MCRPC)

Trial Profile

A Phase 1 Study of A Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 In Patients With Recurrent Metastatic, Castration-Resistant Prostate Cancer (MCRPC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs EC 1169 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Endocyte
  • Most Recent Events

    • 12 Sep 2017 Results related to dose expansion phase (Part B) of the trial were presented at the 42nd European Society for Medical Oncology Congress
    • 05 Sep 2017 According to an Endocyte media release, first part, phase 1a has been completed, recuitment is ongoing for the second part, phase 1b. The trial is expected to complete enrollment in Q3 2017 with a more mature endpoint assessment by end of 2017.
    • 08 Aug 2017 According to an Endocyte media release, updated interim results from this trial will be presented at the European Society for Medical Oncology (ESMO) meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top